Buy, hold, sell: BOQ, Harvey Norman, Lynas shares

Here's what brokers forecast for these three ASX shares over the next 12 months.

Bank of Queensland Ltd (ASX: BOQ), Harvey Norman Ltd (ASX: HVN), and Lynas Rare Earths Ltd (ASX: LYC) shares are in focus today amid a combination of analyst updates and shifting investor sentiment.

Let's find out how these stocks are tracking and what brokers expect next.

two cute young boys dressed in business suits sit amid a pile of papers with a calculator and adding machine looking very happy for themselves.

Image source: Getty Images

Brokers rate Lynas shares as a BUY

Lynas shares have fallen around 2% in Friday morning trade to $14.10 apiece. The shares are now up around 15% for the year to date, but are 17% below trading levels 12 months ago.

The downturn is due to a couple of factors that have combined to create headwinds for the ASX rare earths miner. Geopolitical volatility, higher costs, and investors taking their gains off the table after a strong rally earlier this year have all dampened the share price.

But late last month, the company posted a record FY26 profit and revenue, as company growth continues to ramp up. Lynas reported a 76% increase in revenue and a 282% increase in EBITDA. 

The company also confirmed it is focused on ramping up new assets in FY27 and growing its global presence.

It looks like analysts are excited by Lynas' potential. TradingView data shows the majority have a buy/strong buy rating on the shares. The average $19.57 target price implies a 39% upside, at the time of writing.

Brokers rate Harvey Norman shares as a HOLD

Harvey Norman shares are flat at $4.17 this morning. It's been a difficult year for the retailer, and its shares have shed 41% of their value so far in 2026. They're also 43% lower than 12 months ago.

Harvey Norman has faced strong headwinds this year following renewed concerns about rising inflation and its impact on consumer spending. A tighter household budget means Australians have lowered their discretionary spending this year. 

The experts are on the fence about where the shares could go over the next 12 months. TradingView data shows six (out of 14) analysts have a hold rating on Harvey Norman. Another five rate the shares a sell/strong sell and three rate the shares as a buy/strong buy.

The $4.46 average target price implies a potential 7% upside ahead, at the time of writing.

Brokers rate BOQ shares as a SELL

BOQ shares have been relatively stable through September so far, hovering between $6.50 and $6.70 a piece. It's good news for investors after the ASX bank shares were caught up in a bank-sector-wide sell-off last month. 

At the time of writing, the shares are also flat at $6.51 a piece. The shares are now down around 1% year to date and 9% from 12 months ago.

The bank is scheduled to post its FY26 results in three weeks' time (on the 15th of October), and it looks like investors are sitting tight while they wait for an update on the bank's revenue, net interest margin, and final dividend call.

It looks like the shares are still considered to be trading above fair value. TradingView data shows the majority have a sell/strong sell rating on the shares. The $6.09 average target price implies a downside of around 6% at the time of writing. 

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Lynas Rare Earths Ltd. The Motley Fool Australia has positions in and has recommended Harvey Norman. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

A woman looks excited as she fans out a wad of Aussie $100 notes.
Broker Notes

Macquarie predicts 90% upside and an 8% dividend yield for this ASX share

If the broker is right, this share will pay off nicely.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Young man with a laptop in hand watching stocks and trends on a digital chart.
Broker Notes

Buy, hold, sell: Fortescue, Santos, CBA shares

Let's review some new expert ratings and insights on 3 ASX 200 heavyweights.

Read more »

An unhappy man in a suit sits at his desk with his arms crossed staring at his laptop screen as the PointsBet share price falls
Broker Notes

BHP, Westpac, CSL shares: Buy, sell, or hold?

One of these ASX shares is tipped to fall 13%.

Read more »

Woman tying up her shoelaces before a run.
Broker Notes

Buy, hold, sell: Coles, Wesfarmers, CSL shares

It's a new week and we've got new ratings from the experts.

Read more »

a man in a business suite throws his arms open wide above his head and raises his face with his mouth open in celebration in front of a background of an illuminated board tracking stock market movements.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

Two male ASX investors and executives wearing dark coloured suits sit at a table holding their mobile phones discussing the highest trading ASX 200 shares today
Broker Notes

Buy, hold, sell: Resmed, Goodman Group, CBA shares

We review three fresh buy, hold, and sell calls from John Athanasiou at Red Leaf Securities.

Read more »

colleagues on a lunch break looking at iPhone
Broker Notes

Top brokers name 3 ASX shares to buy now

Here's what brokers are recommending as buys this week.

Read more »